New long-term data presented at AES 2025 indicate reductions in seizure frequency are maintained for up to two years after treatment initiation with bexicaserin in patients with Developmental and Epileptic Encephalopathies (DEEs)1 DEEs are a group of devastating, rare epilepsies...
Hence then, the article about lundbeck announces positive phase 2 long term data for bexicaserin in rare childhood onset epilepsies at american epilepsy society aes annual meeting was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting )
Also on site :
- AI’s real bottleneck is electricity. Who will pay for it?
- Noah Wyle Says Eddie Murphy Told Him to ‘F— Off’ When He Was 9 Years Old, So ‘The Pitt’ Star Always Signs Autographs for Kids Now
- Stora Enso's Board of Directors approves demerger plan to separate Bergslagets Skogar into a new listed company, announcing strategic targets and dividend policy